-
Advances in Clinical Research on Curing Chronic Hepatitis B in NAs-treated Populations by Professor Li Li
Recently, the 25th National Conference on Traditional Chinese Medicine and Hepatobiliary Diseases organized by the Chinese Association of Traditional Chinese Medicine was successfully held in Chongqing. The conference invited distinguished TCM masters, academicians, renowned TCM experts, and hepatology specialists from across the country to deliver academic reports, focusing on the hot and challenging issues in…
-
Xinghai Forum: Professors Baoliang Guo and Guiying Xu Share Research Progress on ctDNA Monitoring in Breast Cancer
Circulating tumor DNA (ctDNA) testing allows for continuous dynamic monitoring of tumor genetic variations without relying on tissue samples. This liquid biopsy technology has been widely used in clinical breast cancer research for prognosis and treatment evaluation, but there are still no standards for ctDNA testing, including population selection, testing frequency, and testing methods. At…
-
Xinghai Forum: Professors Pengfei Qiu and Hao Wang Share Research Progress on ctDNA Monitoring in Breast Cancer
Circulating tumor DNA (ctDNA) testing allows for continuous dynamic monitoring of tumor genetic variations without relying on tissue samples. This liquid biopsy technology has been widely used in clinical breast cancer research for prognosis and treatment evaluation, but there are still no standards for ctDNA testing, including population selection, testing frequency, and testing methods. At…
-
the CHANGEABLE Phase II Study: Niraparib + HX008 for Safe and Effective Treatment of Germline BRCA1/2 Mutated MBC Patients
In recent years, the rapid development of immunotherapy and targeted therapy has continuously updated the treatment strategies for metastatic breast cancer (MBC) patients. PARP inhibitors and immune checkpoint inhibitors, developed based on the concept of synthetic lethality, have become important treatment options for HER2- MBC patients, yet there remains a significant unmet need for treatment.…
-
EHA International Perspective | Professor John Gribben Awarded the José Carreras Prize, Shares Key Factors Advancing Hematology
At the recently held 29th Annual Congress of the European Hematology Association (EHA), Professor John Gribben, former chairman of EHA and head of the Hematological Center at Barts Cancer Institute, Queen Mary University of London, was awarded the José Carreras Prize for his outstanding contributions in the field of immunology research. “Oncology Frontier-Hematology Frontier” specially…
-
EHA International Perspective | Professor Jean-Pierre Bourquin: Advances in Drug Resistance Research for Acute Lymphoblastic Leukemia (ALL)
Acute Lymphoblastic Leukemia (ALL), as an aggressive form of blood cancer, poses a serious threat to patients’ lives. Despite significant progress in treatment in recent years, drug resistance remains a major obstacle to improving patient survival rates and quality of life. At the recently held 29th Annual Congress of the European Hematology Association (EHA 2024),…
-
EHA 2024 | Conference Chairman Professor Antonio Almeida: Join Hands to Create the Future of Hematology Together
The 29th Annual Congress of the European Hematology Association (EHA) was held in Madrid, Spain, from June 13 to 16, 2024. This conference is the largest international event in the field of European hematology, attracting numerous internationally renowned experts and scholars every year to share and discuss innovative ideas, the latest scientific research, and clinical…
-
Xinghai Forum: Professors Yang Zhang and Kejing Zhang Discuss CDK4/6 Inhibitors in Adjuvant Therapy for HR+ Breast Cancer
Cyclin-dependent kinase 4/6 (CDK4/6) inhibitors have brought transformative breakthroughs to the clinical treatment of hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer patients. The combination of CDK4/6 inhibitors and endocrine therapy has become the standard regimen for HR+/HER2- locally advanced and metastatic breast cancer. In the adjuvant treatment phase for early-stage…
Connecting Medical Expertise through Media